A Novel Cerebral Spinal Fluid (CSF) Assay for Assessing HER2 Genetic Heterogeneity and Monitoring Treatment Response in Patients with Leptomeningeal Metastases (LM)

Time: 2:30 pm
day: Day One


    • CNSide is a novel cerebral spinal fluid (CSF)-based assay that uses a combination of cell-based and cell-free DNA (cfDNA) analysis to evaluate patients with CNS metastasis
    • Aids physicians in following:
      • Identification of tumor cells in CSF
      • Characterization of tumor heterogeneity in biomarker targets
      • Monitoring of therapy response with serial quantitative tumor cell counts
    • Can be used to identify HER2 amplification and other actionable biomarkers in patients with breast cancer and suspected or diagnosed LMD